{
    "clinical_study": {
        "@rank": "37027", 
        "brief_summary": {
            "textblock": "The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin\n      for the treatment of anemia in AIDS patients."
        }, 
        "brief_title": "Treatment Program for Anemia in AIDS Patients", 
        "condition": [
            "HIV Infections", 
            "Cytopenias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Anemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Life expectancy < 3 months.\n\n          -  = or < grade 4 performance score.\n\n          -  AIDS-related dementia.\n\n          -  Uncontrolled hypertension.\n\n          -  Acute symptomatic opportunistic infection or other AIDS-defining illness.\n\n        Patients with the following are excluded:\n\n          -  Life expectancy < 3 months.\n\n          -  = or < grade 4 performance score.\n\n          -  AIDS-related dementia.\n\n          -  Uncontrolled hypertension.\n\n          -  Acute symptomatic opportunistic infection or other AIDS-defining illness.\n\n        Patients must  have:\n\n          -  A clinical diagnosis of AIDS.\n\n          -  Hematocrit < 30 percent.\n\n          -  Endogenous serum erythropoietin level = or < 500 U/ml.\n\n          -  A life expectancy = or > 3 months.\n\n          -  > Grade 4 performance score."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002022", 
            "org_study_id": "004G", 
            "secondary_id": "I88-083"
        }, 
        "intervention": {
            "intervention_name": "Epoetin alfa", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "Drugs, Investigational", 
            "Erythropoietin", 
            "Acquired Immunodeficiency Syndrome", 
            "Anemia", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Raritan", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "088690602"
                }, 
                "name": "R W Johnson Pharmaceutical Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment Program for Anemia in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002022"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "R W Johnson Pharmaceutical Research Institute", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1991"
    }, 
    "geocoordinates": {
        "R W Johnson Pharmaceutical Research Institute": "40.57 -74.633"
    }
}